John Maris

76PUBLICATIONS
543CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (76)

|Jun 13, 2026
The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity.

|Jun 04, 2026
A generalizable system for antigenic peptide targeting across HLA-I allotypes.

|Apr 13, 2026
IL1RAP antibody-drug conjugates potently target primary and metastatic disease in multiple oncofusion-driven cancers.

Hai-Feng Zhang, Edouard De Dreuzy, Yue Zhou Huang

|Apr 06, 2026
PRECLINICAL ACTIVITY OF THE B7-H3- TARGETING ANTIBODY-DRUG CONJUGATE (ADC) VOBRAMITAMAB DUOCARMAZINE (VOBRA DUO) IN PEDIATRIC SOLID TUMORS.

Edward Favours, Haiying Tang, Peyton Wong

|Jan 01, 2026
HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors.

Daniel Hwang, Molly C Erdman, Santosh Adhikari

|Nov 07, 2025
Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma.

Jarrett Lindsay, Jonathan Gaither, David Groff

Pageof 13

Frequent Collaborators

13 joint publications

Yaël P Mossé

11 joint publications

David Groff

9 joint publications

Rochelle Bagatell

9 joint publications

Alvin Farrel